Top

Cancer Immunology, Immunotherapy

Published in:

01-03-2012 | Letter to the editors

Response to the rebuttal letter of Kountouras and colleagues regarding the paper by Codolo et al. ‘HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response’

Authors: Andrew M. Jackson, Hester A. Franks

Published in: Cancer Immunology, Immunotherapy | Issue 3/2012

Excerpt

Dear Editors …

Codolo G, Fassan M, Munari F, Volpe A, Bassi P, Rugge M, Pagano F, D’Elios MM, de Bernard M (2011) HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response. Cancer Immunol Immunother. doi:10.1007/s00262-011-1087-2

Alexandroff AB, Nicholson S, Patel PM, Jackson AM (2010) Recent advances in BCG immunotherapy in malignancy. Immunotherapy 2:551–560PubMedCrossRef

Alexandroff AB, Jackson AM, O’Donnell MA, James K (1999) BCG immunotherapy of bladder cancer: 20 years on. Lancet 353:1689–1694PubMedCrossRef

Jackson AM, James K (1994) Understanding the most successful immunotherapy for cancer. Immunologist 2:208–215

Luo Y, Henning J, O’Donnell MA (2011) Th1 cytokine secreting recombinant mycobacterium bovis Bacillus Calmette-Guerin and prospective use in immunotherapy of bladder cancer. Clin Dev Immunol. doi:10.1155/2011/728930

Rosevear HM, Lightfoot AJ, Birusingh KK, Maymí JL, Nepple KG, O’Donnell MA, National BCG/interferon investigator group (2011) Factors affecting response to bacillus clamette-gurein plus interferon for urothelial carcinoma in situ. J Urol 186:817–823PubMedCrossRef

de Bernard M, D’Elios MM (2010) The immune modulating activity of Helicobacter pylori HP-NAP: friend or foe? Toxicon 15:1186–1192CrossRef

Gavalas E, Kountouras J, Deretzi G, Boziki M, Zavos C, Venizelos I (2007) Letter to Editor: Helicobacter pylori and multiple sclerosis. J Neuroimmunol 188:187–189

Li W, Minohara M, Piao H, Matsishita T, Masaki K, Matsuoka T, Isobe N, Su JJ, Ohyagi Y, Kira J (2009) Association of anti-Helicobacter pylori neutrophil-activation protein antibody response with anti-aquaporin-4 autoimmunity in Japanese patients with multiple scleroisis and neuromyelitis optica. Mult Scler 15:1411–1421PubMedCrossRef

10.

Kountouras J et al (2010) Letter to Editor: Helicobacter pylori with or without its neutrophil-activating protein may be the common denominator associated with multiple sclerosis and neuromyelitis optica. Mult Scler 16:376–377

11.

Yool AJ (2007) Aquaporins: multiple roles in the central nervous system. Neuroscientist 13:470–485PubMedCrossRef

12.

Venero JL, Vizuete ML, Machado A, Cano J (2001) Aquaporins in the central nervous system. Prog Neurobiol 63:321–336PubMedCrossRef

13.

Li W, Minohara M, Su JJ, Matsuoka T, Osoegawa M, Ishizu T, Kira J (2007) Helicobacter pylori infection is a potential protective factor against conventional multiple sclerosis in the Japanese population. J Neuroimmunol 184:227–231PubMedCrossRef

14.

Wender M (2003) Prevalence of Helicobacter pylori infection among patients with multiple sclerosis. Neurol Neurochir Pol 37:45–48PubMed

15.

Radic M, Kaliterna DM, Rosic J (2011) Heliocbacter pylori infection and systemic sclerosis—is there a link? Joint Bone Spine 78:337–340PubMedCrossRef

Title: Response to the rebuttal letter of Kountouras and colleagues regarding the paper by Codolo et al. ‘HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response’
Authors: Andrew M. Jackson
Hester A. Franks
Publication date: 01-03-2012
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 3/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-011-1144-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2012

In vivo electroporation restores the low effectiveness of DNA vaccination against HER-2/neu in aging

Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome

SCF and TLR4 ligand cooperate to augment the tumor-promoting potential of mast cells

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens

Integrin alphavbeta6 promotes tumor tolerance in colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer